X4 Pharmaceuticals Stock Discussion

$X4 Pharmaceuticals (XFOR.US)$
X4 Pharmaceuticals Inc - to Submit Maa to EMA for Mavorixafor in Whim Syndrome

$X4 Pharmaceuticals (XFOR.US)$
X4 Pharmaceuticals Inc - to Receive €28.5 Mln Upfront, up to €226 Mln in Milestones

$X4 Pharmaceuticals (XFOR.US)$
X4 Pharmaceuticals and Norgine Enter Into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

$X4 Pharmaceuticals (XFOR.US)$
👀

$X4 Pharmaceuticals (XFOR.US)$ Reuters· 1 min ago
X4 Pharmaceuticals and Norgine Enter Into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

$X4 Pharmaceuticals (XFOR.US)$
X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
Monday, 13th January at 7:35 am
X4 to receive a €28.5 million upfront payment and up to €226 million in potential regulatory and commercial milestone payments in addition to tiered, double-digit royalties up to the mid-twenties
Upfront non-dilutive funds strengthen X4's balance sheet as enrollment ramps up in the company's gl...